Running title: Molecular epidemiology of COVID-19 in Latin America

Authors: Diana M. Rojas-Gallardo,[1],(https://orcid.org/0000-0002-7902-2231) Sandra C. Garzón-

Castaño,[1](https://orcid.org/0000-0002-9547-967X), Natalia Millán[2], Erika V. Jiménez-Posada [4,5]

(http://orcid.org/0000-0002-3737-9427)**,** Marlen Martínez-Gutiérrez[5,6], (https://orcid.org/0000-0002-9429-0058),

Julian Ruiz-Saenz[5],(https://orcid.org/0000-0002-1447-1458), Jaime A. Cardona-Ospina.[1,2,3,4*]

(https://orcid.org/0000-0003-3996-2293)

Affiliations: [1]Grupo de Investigación Biomedicina, Facultad de Medicina, Fundación

Universitaria Autónoma de las Américas, Pereira, Risaralda, Colombia. [2]Semillero de

Investigación en Infecciones Emergentes y Medicina Tropical, SIEM, Fundación

Universitaria Autónoma de las Américas, Pereira, Risaralda, Colombia, [3]Public Health and

Infection Research Group, Faculty of Health Sciences, Universidad Tecnológica de Pereira,

Pereira, Risaralda, Colombia. [4]Emerging Infectious Diseases and Tropical Medicine

Research Group. Instituto para la Investigación en Ciencias Biomédicas - Sci-Help, Pereira,

Risaralda, Colombia. [5]Grupo de Investigación en Ciencias Animales - GRICA, Facultad de

Medicina Veterinaria y Zootecnia, Universidad Cooperativa de Colombia, Bucaramanga,

Colombia. [6]Infettare, Facultad de Medicina, Universidad Cooperativa de Colombia,

Medellín, Colombia.

*Corresponding author: Jaime A. Cardona-Ospina, Phone +57 311 339 5249, Fundación

Universitaria Autónoma de las Américas, Bloque B, Av. de las Américas #98-56 Sector

Belmonte, Pereira, Risaralda, Colombia, Postal Code: 660001, e-mail:

jaime.cardona@uam.edu.co

Words: 3140 Limit: 3500 | Abstract: 241 | Figures: 3 | Tables: 2 | Supplementary Tables: 4 |

Supplementary Figures: 1

Abstract:

Background: SARS-CoV-2 revealed important gaps in infectious disease surveillance.

Molecular epidemiology can help monitoring and adapting traditional surveillance to

surpass those limitations. This work aims to contrast data driven from traditional

surveillance with parameters inferred from molecular epidemiology in Latin America

(LATAM) **Methods:** We obtained epidemiological data up to 4th June, 2020. We estimated

Effective Reproductive Number (Re) and epidemic curves using maximum likelihood

(ML). SARS-CoV-2 genomes were obtained from GISAID up to June 4th 2020. We aligned

sequences, generated a ML phylogenetic tree, and ran a coalescent model Birth Death SIR.

Phylodynamic analysis was performed for inferring Re, number of infections and date of

introduction. **Findings:** A total of 1,144,077 cases were reported up to 4th June 2020.

Countries with the largest cumulative cases were Chile, Peru and Panama. We found at

least 18 different lineages circulating, with a predominance of B.1 and B.1.1. We inferred

an underestimation of the daily incident cases. When contrasting observed and inferred Re,

we did not find statistically significant differences except for Chile and Mexico. Temporal

analysis of the introduction of SARS-CoV-2 suggested a detection lag of at least 21 days.

Interpretation: Our results support that epidemiological and genomic surveillance are two

complementary approaches. Even with a low number of genomes proper estimations of Re

could be performed. We suggest that countries, especially developing countries, should

consider to add genomic surveillance to their systems for monitoring and adapting

epidemiological control of SARS-CoV-2. **Funding:** None.

Keywords:

SARS-CoV-2, COVID-19, Phylodynamic, Molecular Epidemiology, Latin America

Introduction:

SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus - 2) the causative agent of COVID-19, has revealed the need for better, more accurate, more expedite, and widely available surveillance tools, for improving infectious disease detection and control. The fact that COVID-19 control relies up to this moment on proper disease surveillance, due to the lack of an approved vaccine or effective treatment, obliged to promptly establish early detection strategies of cases and contacts for rapid implementation of patient isolation.[1] However, traditional epidemiological surveillance methods are subjected to limitations inherent to the ability of each health system of capturing and properly diagnosing and following symptomatic and asymptomatic cases and contacts.[2]

These limitations lead often to underestimation of the number of cases and real burden of the disease,[3] and are usually overcome through community based studies, like for example serological surveys. These, allow an "a posteriori" estimation of the expansion factor for adjusting the real number of cases during an epidemic.[4] Notwithstanding, in the context of the current pandemic, there is a need for almost real-time assessment of case underestimation for adjusting containment measures and facilitate disease control. In Latin American countries (LATAM) this is particularly important since differences in demography, social structure and health care availability can limit the effect of strategies for controlling the spread of the virus.[5].

In this context, as new molecular tools have been integrated into disease surveillance, and mathematical models for the understanding of the relationship of pathogen evolution and

transmission dynamics have been developed,[6,7] molecular epidemiology has presented

solutions to the limitations of traditional surveillance systems.[8] Phylodynamic inference

allows the estimation of susceptible, infected and recovered cases, and phylogeographic

analysis allows the assessment of transmission chains and temporospatial distribution of

infections.[7] Therefore, this study pretends to contrast data driven from epidemiologic

surveillance in LATAM, after the first one hundred days of pandemic, with parameters

inferred from phylodynamic analysis of reported genomes of SARS-CoV-2 across different

countries, in order to compare the inferred versus the observed number of cases, and

perform a temporal analysis of the introduction of SARS-CoV-2 to each country.

Materials and Methods

Study design and setting

This is a molecular epidemiology study based on public epidemiologic and genomic data of

SARS-CoV-2 in LATAM up to 4th June, 2020 (One hundred days after the first detection of

the virus in Brazil on February 25, 2020)[9]. For its reporting, we adhered the Strengthening

the Reporting of Molecular Epidemiology for Infectious Diseases (STROME-ID)

statement.[10]

Data sources

COVID-19 epidemiological surveillance data was obtained from data published by the

European Centre for Disease Prevention and Control until 4th June, 2020, including only

countries belonging to LATAM as defined by the Pan American Health Organization

(PAHO). Epidemiological information obtained from this surveillance was contrasted with

information inferred from phylodynamic analysis of complete genomes of SARS-CoV-2 in

LATAM reported to GISAID up to 4th June, 2020.[11] Information about laboratories that

reported this information is publicly available at https://www.gisaid.org/. We searched for

sequences reported for North and South America up to June 4th 2020. We choose only

whole genome sequences (>29,900) with high coverage, and more than 95% of nucleotide

base resolved belonging to countries from LATAM as previously defined.

Epidemiological analysis

Daily incident cases, dates of introduction and fatal cases were obtained. We calculated

Case Fatality Rates (CFR) = number of reported deaths/number of total cases) X 100, and

estimated the effective reproductive number (Re) and epidemiologic curves using

maximum likelihood (ML) methods with the *R0 v 1.2-6* package for R [12,13]. In order to

estimate Re, we estimated the distribution of the generation time (GT), considered as the

time between a primary infected case and a secondary case, through ML using the serial

time between infectee/infector pairs published by He *et al*, 2020.[12,14] Then, Re at the

beginning of the epidemic, and its evolution through time were estimated.[13] The time

period over which growth was exponential was estimated using the deviance R-squared

statistic over a range of possible time periods.[12]

Phylogenetic analysis

We conserved identical sequences with different sampling dates and different location and

discarded identical sequences with same sampling date within countries. Accession IDs,

sampling dates and locations of the sequences were obtained. We also generated subgroup

datasets for each country reporting at least five sequences for performing phylodynamic

analysis. Sequences were aligned using MAFFT software v7.450 and visually inspected

and edited using Bioedit v7.0.5.3. To assess for viral recombination, we employed the

pairwise homoplasy index (PHI) test using SplitsTree v4.15.1. Nucleotide substitution

model for the alignment was inferred according to the corrected Akaike information

criterion (AICc) in jModelTest v2.1.10. The ML tree was inferred using PhyML software

V3.0 (DOI: 10.1093/sysbio/syq010) with an approximate likelihood-ratio test (aLRT)

approach. Phylogenetic lineages were defined as previously reported by Rambaut et al.,[15]

by using the PANGOLIN (Phylogenetic Assignment of Named Global Outbreak LINeages)

COVID-19 Lineage Assigner web tool (Available at https://pangolin.cog-uk.io/).

Coalescent and Phylodynamic analysis

In order to infer and contrast molecular epidemiology data about cumulative infections and

Re, we performed a phylodynamic analysis for each country with at least five included

sequences. For each country data set, coalescent model Birth Death SIR (serial)[16] was run

with *Phylodynamics* package in BEAST v2.6.2.0. Priors were introduced with BEAUti and

all data sets were run with the same prior distribution and value for Molecular clock rate

(0.0006), Become Uninfectious Rate (Normal (mean=37.0, sigma =1.3)) and Reproductive

Number (Log-normal (mean log=0,0, sd log =1.2)). Markov chain Monte Carlo (MCMC)

runs of 80 million states sampling every 8,000 steps were computed. The convergence of

MCMC chains was checked using Tracer v.1.7.1, ensuring that the effective sample size

(ESS) values were greater than 300 for each parameter estimated; for each data set, the

maximum clade credibility (MCC) tree was obtained from the trees posterior distribution

using TreeAnnotator after 10% burn-in. Finally, time scaled phylogenies, substitution rates,

and TMRCA were estimated using the *treedater* R package 0.5.0 assuming an strict

molecular clock. Re evolution through time was estimated using the *skyspline* R package

0.1, and SIR trajectories were calculated using the *phydynR* R package 0.2.0[17] using an

exponential growth model using birth rates, death rates and effective population number

(Ne) estimated by BEAST for each country.

Sensitivity analysis

We conducted a sensitivity analysis computing the R-squared statistic over a

range of possible time periods for exponential growth (begin between days 1 to 50, and

ending between days 51 to 100), selecting the best fit for ML analysis. In order to assess the

effect of GT distribution variation on Re estimation, we computed the reproduction ratio

over a range of chosen GT distributions with mean between 1 to 14 days, assuming fixed

standard deviation, and using ML method.

Role of the funding source

We did not have any funding source for funding this research. All the authors had full

access to all the data in the study and had final responsibility for the decision to submit for

publication.

Results

Epidemiological analysis of COVID-19 in LATAM

A total of 1,144,077 cases were reported up to 4th June 2020, with 57,453 deaths (overall

CFR 3·45%). At the day 100 after the introduction of COVID-19 in LATAM, the countries

with largest number of cumulative cases were: Brazil (584,016 cases), Peru (178,914

cases), and Chile (113,628) cases). But when adjusting by cases by 10^6 population, the

countries with the largest cumulative cases were Chile (6,066·99 cases x 10^6 population),

Peru (5,592·94 cases x 10^6 population), and Panama (3,497·59 cases x 10^6 population).

On the other hand, Mexico, Ecuador and Brazil were the countries with the highest CFR

with 11·58%, 7·42%, and 5·57%, respectively (Table 1).

The overall Re for LATAM estimated through ML was 1·27 (CI95% 1·26 to 1·27). The

epidemic curve and time dependent analysis is showed in Figure 1. The portion of the

epidemic curve that best fitted exponential growth was estimated between 03-19-2020 and

05-31-2020, with a growth rate of 0·05%, and Re of 1·342 (IC95% 1·341 to 1·342) during

that period of time. Sensitivity analysis showed that Re remained within the 95%IC only

for a small choice of time windows, and that varied significantly across different GT

distributions (data not shown). In order to compare the evolution of the pandemic in each

LATAM country over time, we analyzed the number of cumulative cases per 10^6

population at day 50 of introduction to each country. At this time, the country with the

highest number of cumulative cases per 10^6 population was Panama, followed by Peru,

and Ecuador (Table 1), although the highest Re corresponded to Salvador, Mexico and

Brazil.

Phylogenetic Analysis of SARS-CoV-2 in LATAM

A total of 439 genomic sequences were retrieved from GISAID library,[11] and after quality

clearance 357 genomic sequences, from 8 countries, were finally included for analysis

(Supplementary Table 1). Substitution rates for every data set is showed in Supplementary

Table 2. The PHI test did not find statistically significant evidence for recombination for

any of the tested data set. The genomic phylogenetic relation by both, ML and

PANGOLIN, showed that SARS-CoV-2 in LATAM includes at least 18 different lineages,

with a predominance of B.1 and B.1.1 lineages all across the continent representing 66% of

the total included sequences (Supplementary Table 3, Figure 2). Early sequences included

the most ancestral A and B lineages that started the pandemic in Hubei, China, indicating

the premature SARS-CoV-2 circulation in LATAM through travelers. However, there were

important differences at country level. Although lineage B.1 were highly reported across

different countries; in some other like Mexico and Uruguay, lineages A.1 and A.5

predominated (Supplementary Figure 1).

Coalescent and Phylodynamic Analysis

To properly contrast observed epidemiologic curves with phylodynamic inferences, we

performed subgroup analysis including only countries with at least five reported genomic

sequences and estimating epidemiological observed Re up to the date of the last sampled

sequence (LSS). Therefore, only seven countries were finally included in the subgroup

analysis; Argentina (LSS 04-19-2020, n = 24), Brazil (LSS 04-27-2020, n = 84), Colombia

(LSS 04-07-2020, n = 68), Mexico (LSS 03-21-2020, n = 20), Chile (LSS 04-06-2020, n =

147) Costa Rica (LSS 03-25-2020, n = 5) and Uruguay (LSS 04-21-2020, n = 7). Posterior

summary of epidemiological and evolutionary and demographic parameters for each dataset

are shown in Supplementary Table 4.

After demographic model estimation, phylodynamic analysis showed an underestimation of

the daily incident cases in a factor that varied among countries between 2 to 2200 times

compared with data reported to surveillance systems (Figure 3, Table 2). According to our

phylodynamic estimations the percentage population infected up to the date of LSS for each

country were for Argentina 0·38% (IC95% 0·33 to 0·61), Brazil 1·54% (IC95% 0·86 to

3·37), Chile 1·18% (IC95% 0·76% to 2·13), Colombia 0·22% (0·15 to 0·41), Costa Rica

7·81% (IC95% 5·11 to 14·57), Mexico 0·10% (0·09 to 0·19), and Uruguay 3·5% (2·16 to

8·45), and the percentage of infections diagnosed were for Argentina 4·32 (IC95% 2·71 to

4·94), Brazil 62·16% (IC95% 28·36 to 100), Chile 2·03% (1·12 to 3·13), Colombia 2·15%

(1·43 to 0·78), Costa Rica 0·05% (0·02 to 0·07), Mexico 0·17% (IC95% 0·09 to 0·19),

Uruguay 0·44 IC95% (0·18 to 0·72). However, when contrasting epidemiological and

phylodynamic inferred Re, we did not find statistically significant differences at the cut-off

time, except for Chile and Mexico, Table 2. Finally, temporal analysis of the introduction

of SARS-CoV-2 revealed that the virus was circulating at least during 21 days before viral

detection, except for Uruguay, in which the period was 10 days, and Costa Rica, in which

there were not differences between the time of first case notification and TMRA.

Discussion:

SARS-CoV-2 transmissibility and epidemiology have varied widely across the world,[18]

apparently related with effectiveness of containment measures, and the time of their

implementation. After between the first 100 days of introduction, LATAM have become

the epicenter of the COVID-19 pandemic. The magnitude it can reach have raised concern

considering the complex sociopolitical scenario in the region[19] and also the differential

impact that the pandemic can have, not only in terms of burden of disease directly derived

from COVID-19, but also from diverting public health efforts to only one disease, and from

economic effects of containment measures.[5]

To assess the real magnitude of the pandemic will help to estimate the real role and need of

containment measures, and will help to propose strategies for adapting them to the current

needs, helping balance cost-benefit of those measures. At this respect, our results revealed

an overall agreement in terms of transmissibility between epidemiological observed and

phylodynamic inferred data, but suggested an overall under detection of COVID-19 cases

in LATAM. Importantly, the country with the largest inferred number of underreported

cases was Costa Rica, one of the countries with lower cases detected through traditional

epidemiological surveillance, while countries with largest cumulative cases like Brazil,

Chile and Argentina had a lower estimated underreporting.

Notwithstanding, this data should be interpreted cautiously. In the case of Costa Rica only

samples collected very early in the pandemic were included. This implies that the increased

variability detected could be product of multiple introductions into the country at the

beginning of the pandemic rather than from cumulated mutations through transmission

chains in time, which could lead to an overestimation of the number of cases. This

explanation is supported by the fact that phylogenetic analysis revealed different linages

circulating early in the pandemic, and that the TMRA coincided with the time of

epidemiological detection of the virus in the country, showing that SARS-CoV-2 was

circulating in Costa Rica for less than a week before first case detection. This could be also

the case of Uruguay, in which only seven sequences were finally included for

phylodynamic analysis. In this country, after SARS-CoV-2 detection, public health

authorities lead to early declaration of the sanitary emergency, with high number of tests

per millions of habitants compared with neighbor countries like Brazil, Argentina and

Paraguay. In this particular country, availability of more recent genome sequences would

be desirable in order to assess the effect of the implemented measures.

Additionally, more than the 50% of the included sequences for Brazil and Mexico were

sampled in a same geographical area. This could entail that cumulated variability were

product of local transmission chains more than national level transmission, leading to an

underestimation of the cases for these countries. Nonetheless, new available data can help

to surpass this limitation, particularly for Brazil. According to Candido et al,[20] when a data

set of 427 new sequences were added to the GISAID available sequences up to 30 April, a

strong spatial representativity of the country was found. Therefore, a subsequent analysis of

this data could provide insights in to the real magnitude of the pandemic in this country.

On the other hand, although our estimations of the percentage of population infected for

Argentina, Brazil, Chile and Colombia significantly differ from modelled seroprevalence

estimations for those countries,[21] our estimations of the percentage of undiagnosed

infections are similar to those showed by seroprevalence studies. According to our results,

at least the 96% of the infections in the analyzed countries (excluding Brazil) are not

diagnosed, that agrees with serological community based studies in Hubei, China that

suggests that 97% of infections might have gone undiagnosed during the epidemic, [22] and

in Geneva, Switzerland that showed that for every confirmed case there were 11.6

infections in the community.[23]

Regarding transmissibility, the Re was in good agreement for every country, except for

Chile and Mexico, and is consistent with previous estimations for Latin American

countries[24-27]. This has two important implications: First, the good agreement at this respect

validates previous transmission dynamics of viral shedding estimated by He, X, *et al*,[14]

suggesting that transmission in LATAM have had a similar behavior to the observed in

other countries, and second, rise concern about the effectiveness of containment measures

implemented in Chile and Mexico. On the other hand, the fact that most of the countries

had a detection lag of at least 21 days, highlights the need of improvement of index case

detection in local healthcare systems.

As reported by others for the Europe and North American outbreaks,[15,28] in LATAM the

B.1 lineage was one of the first lineages that was stablished and was the most prominent

lineage that spread with B.1.1 lineage. Although it has been claimed that B.1 lineage

harbors a D614G mutation in the Spike protein that make the virus more contagious,[29] our

results about the early circulation of B.1 lineage in LATAM and the fact that not all the

countries that has B.1 has a high prevalence over other lineages, it cannot be confirmed that

that D614G showed high fitness as has been reported.[28,30]

Nevertheless, our estimations have some limitations. First, the quality of the inferred

phylodynamic data for each country depends on the extent of the geospatial genome

sampling. For some countries like for example Brazil and Mexico, samples were limited in

a high proportion to a particular geographical area within the countries, and hence

estimations may not necessarily reflect data generalizable to the entire country. On the

other hand, the limited availability of clinical and epidemiological metadata do not allow to

properly evaluate transmission chains within the countries. Therefore, observed variability

could not be related to cumulated mutation through transmission chains, but to different

introductions to each country, as suggested by the co-circulation of multiple lineages. The

lack of availability of enough samples from other countries limited the number of countries

to be included in the phylodynamic analysis.

Finally, our results support that epidemiological and genomic surveillance are two

complementary approaches for analysis of transmission and epidemiological patterns

within and between countries. Overall Re estimation for LATAM through phylodynamic

analysis showed good agreement with observed Re through epidemiological surveillance

even when a large amount of sequences were not available for every country. The evidence

suggests that even with a low number of sequences, proper estimations of Re could be

performed. This could provide important insights, especially at the beginning of an

epidemic when epidemiological surveillance systems are adjusting follow-up and control

measures. At the same time, we found that the lack of clinical and epidemiological

metadata for reported sequences difficult making phylodynamic inferences. We suggest

that countries, especially developing countries, should consider to add genomic surveillance

to their systems for monitoring and adapting epidemiological surveillance of SARS-CoV-2.

Authors contributions:

Diana M. Rojas-Gallardo: Study design, data analysis, data interpretation, and manuscript

writing*, Sandra C. Garzón-Castaño: data analysis, data interpretation, and manuscript

writing, Natalia Millán: data collection, data analysis, and manuscript writing, Erika V.

Jiménez-Posada: data collection, data analysis, and manuscript writing, Marlen Martínez-

Gutiérrez: data analysis, data interpretation and manuscript writing, Julian Ruiz-Saenz: data

analysis, data interpretation, data analysis, and manuscript writing, Jaime A. Cardona-

Ospina: Study design, data analysis, data interpretation, and manuscript writing*

*These two authors contributed equally.

Acknowledgements:

We would like to acknowledge Grupo de Investigación SIRIUS, Facultad de Ingenierias,

Universidad Tecnológica de Pereira, for providing resources for performing high

performance computational analysis.

Declaration of interests:

The authors have nothing to disclose.

References

1. Roxby AC, Greninger AL, Hatfield KM, et al. Detection of SARS-CoV-2 Among Residents and Staff Members of an Independent and Assisted Living Community for Older Adults - Seattle, Washington, 2020. *MMWR Morb Mortal Wkly Rep* 2020; **69**(14): 416-8.

2. Sáez-López E, Pechirra P, Costa I, et al. Performance of surveillance case definitions for respiratory syncytial virus infections through the sentinel influenza surveillance system, Portugal, 2010 to 2018. *Euro Surveill* 2019; **24**(45).

3. Gibbons CL, Mangen M-JJ, Plass D, et al. Measuring underreporting and under-ascertainment in infectious disease datasets: a comparison of methods. *BMC Public Health* 2014; **14**: 147-.

4. Toan NT, Rossi S, Prisco G, Nante N, Viviani S. Dengue epidemiology in selected endemic countries: factors influencing expansion factors as estimates of underreporting. *Trop Med Int Health* 2015; **20**(7): 840-63.

5. Walker PGT, Whittaker C, Watson OJ, et al. The impact of COVID-19 and strategies for mitigation and suppression in low- and middle-income countries. *Science* 2020.

6. Grenfell BT, Pybus OG, Gog JR, et al. Unifying the epidemiological and evolutionary dynamics of pathogens. *Science* 2004; **303**(5656): 327-32.

7. Volz EM, Koelle K, Bedford T. Viral phylodynamics. *PLoS Comput Biol* 2013; **9**(3): e1002947.

8. Rodriguez-Morales AJ, Balbin-Ramon GJ, Rabaan AA, et al. Genomic Epidemiology and its importance in the study of the COVID-19 pandemic. *Infez Med* 2020; **28**(2): 139-42.

9.   Rodriguez-Morales AJ, Gallego V, Escalera-Antezana JP, et al. COVID-19 in Latin

America: The implications of the first confirmed case in Brazil. *Travel Med Infect Dis*

2020; **35**: 101613.

10.   Field N, Cohen T, Struelens MJ, et al. Strengthening the Reporting of Molecular

Epidemiology for Infectious Diseases (STROME-ID): an extension of the STROBE

statement. *Lancet Infect Dis* 2014; **14**(4): 341-52.

11.   Elbe S, Buckland-Merrett G. Data, disease and diplomacy: GISAID's innovative

contribution to global health. *Glob Chall* 2017; **1**(1): 33-46.

12.   Obadia T, Haneef R, Boelle PY. The R0 package: a toolbox to estimate

reproduction numbers for epidemic outbreaks. *BMC Med Inform Decis Mak* 2012; **12**: 147.

13.   Wallinga J, Lipsitch M. How generation intervals shape the relationship between

growth rates and reproductive numbers. *Proc Biol Sci* 2007; **274**(1609): 599-604.

14.   He X, Lau EHY, Wu P, et al. Temporal dynamics in viral shedding and

transmissibility of COVID-19. *Nat Med* 2020; **26**(5): 672-5.

15.   Rambaut A, Holmes EC, Hill V, et al. A dynamic nomenclature proposal for SARS-

CoV-2 to assist genomic epidemiology. *bioRxiv* 2020: 2020.04.17.046086.

16.   Kuhnert D, Stadler T, Vaughan TG, Drummond AJ. Simultaneous reconstruction of

evolutionary history and epidemiological dynamics from viral sequences with the birth-

death SIR model. *J R Soc Interface* 2014; **11**(94): 20131106.

17.   Volz EM, Siveroni I. Bayesian phylodynamic inference with complex models. *PLoS*

Comput Biol 2018; **14**(11): e1006546.

18.   European Centre for Disease Prevention and Control. Geographic distribution of

COVID-19 cases worldwide. 2020. https://www.ecdc.europa.eu/en/publications-

data/download-todays-data-geographic-distribution-covid-19-cases-worldwide (accessed 13

May 2020).

19.   Burki T. COVID-19 in Latin America. *Lancet Infect Dis* 2020; **20**(5): 547-8.

20.   Candido DdS, Claro IM, de Jesus JG, et al. Evolution and epidemic spread of

SARS-CoV-2 in Brazil. *medRxiv* 2020: 2020.06.11.20128249.

21.   Matabuena M, Mier PR, Meijide-Garcia C, Leboran V, Gude F. Mathematical

estimation of COVID-19 prevalence in Latin America. *medRxiv* 2020.

22.   Neto OP, Reis JC, Brizzi ACB, et al. Mathematical model of COVID-19

intervention scenarios for Sao Paulo- Brazil. *medRxiv* 2020: 2020.04.26.20081208.

23.   Stringhini S, Wisniak A, Piumatti G, et al. Seroprevalence of anti-SARS-CoV-2 IgG

antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. *Lancet*

2020.

24.   Caicedo-Ochoa Y, Rebellon-Sanchez DE, Penaloza-Rallon M, Cortes-Motta HF,

Mendez-Fandino YR. Effective Reproductive Number estimation for initial stage of

COVID-19 pandemic in Latin American Countries. *Int J Infect Dis* 2020; **95**: 316-8.

25.   Chakraborty A, Chen J, Desvars-Larrive A, et al. Analyzing Covid-19 Data using

SIRD Models. *medRxiv* 2020: 2020.05.28.20115527.

26.   Mellan TA, Hoeltgebaum HH, Mishra S, et al. Report 21: Estimating COVID-19

cases and reproduction number in Brazil. *medRxiv* 2020: 2020.05.09.20096701.

27.   Prete CA, Buss L, Dighe A, et al. Serial Interval Distribution of SARS-CoV-2

Infection in Brazil. *medRxiv* 2020: 2020.06.09.20127043.

28.   Worobey M, Pekar J, Larsen BB, et al. The emergence of SARS-CoV-2 in Europe

and the US. *bioRxiv* 2020: 2020.05.21.109322.

29.   Korber B, Fischer W, Gnanakaran S, et al. Spike mutation pipeline reveals the

emergence of a more transmissible form of SARS-CoV-2. *bioRxiv* 2020:

2020.04.29.069054.

30.   Isabel S, Graña-Miraglia L, Gutierrez JM, et al. Evolutionary and structural analyses

of SARS-CoV-2 D614G spike protein mutation now documented worldwide. *bioRxiv* 2020:

2020.06.08.140459.

Table 1. Epidemiological summary of COVID-19 epidemiology in Latin American countries up to June 4th 2020.

Country	Reported Cases	Cases x 10^6 pop*	Deaths	CFR	Days after introduction	Re	CI95%	Reported Cases[50]	Cases[50] x 10^6 pop	Re[50]	CI95%	Genome Sequences Included
Venezuela	1952	67·61	20	1·02	82	1·44	1·35 to 1·53	345	11·95	1·06	0·91 to 1·24	0
Costa Rica	1157	231·43	10	0·86	89	1·11	1·02 to 1·21	693	138·62	1·06	0·95 to 1·17	5
Uruguay	828	240·05	23	2·78	82	1·02	0·93 to 1·12	652	189·02	1·08	0·96 to 1·20	7
Nicaragua	1118	172·92	46	4·11	78	1·68	1·55 to 1·82	16	2·47	1·1	0·49 to 2·08	0
Paraguay	1070	153·82	11	1·03	85	1·12	1·02 to 1·22	249	35·80	1·14	0·94 to 1·36	0
Cuba	2107	185·83	83	3·94	82	1·04	0·98 to 1·11	1611	142·09	1·2	1·11 to 1·28	0
Panama	14609	3497·59	357	2·44	87	1·18	1·15 to 1·21	6021	1441·51	1·24	1·20 to 1·29	1
Argentina	19255	432·75	583	3·03	90	1·31	1·29 to 1·34	3423	76·93	1·25	1·19 to 1·32	24
Chile	113628	6066·90	1275	1·12	92	1·31	1·30 to 1·32	11296	603·12	1·28	1·25 to 1·32	147
Ecuador	46998	2750·94	3486	7·42	91	1·06	1·04 to 1·07	11183	654·58	1·31	1·27 to 1·35	0
Honduras	5690	593·48	234	4·11	83	1·23	1·18 to 1·28	899	93·77	1·32	1·19 to 1·46	0
Colombia	33354	671·80	1045	3·13	86	1·31	1·29 to 1·33	5949	119·82	1·33	1·28 to 1·39	68
Guatemala	5760	333·96	143	2·48	82	1·32	1·27 to 1·36	688	39·89	1·39	1·25 to 1·54	0
Bolivia	11638	1025·09	400	3·44	84	1·37	1·34 to 1·41	1167	102·79	1·43	1·31 to 1·55	0
Dominican Republic	18040	1697·54	516	2·86	86	1·15	1·12 to 1·17	6416	603·74	1·45	1·39 to 1·51	0
Peru	178914	5592·94	4894	2·74	89	1·22	1·21 to 1·23	25331	791·86	1·47	1·44 to 1·50	1
Brazil	584016	2788·07	32548	5·57	100	1·3	1·30 to 1·31	25262	120·60	1·53	1·51 to 1·56	84
Mexico	101238	802·26	11728	11·58	89	1·28	1·28 to 1·30	13842	109·69	1·57	1·52 to 1·62	20
El Salvador	2705	421·29	51	1·89	78	1·2	1·14 to 1·27	695	108·24	1·59	1·43 to 1·76	0

*Demographic information was obtained as reported by the European Centre for Disease Prevention and Control, [50]Correspond to data estimated until the day 50 of SARS-CoV-2 introduction to each country. Effective Reproductive Numbers (Re) were estimated using Maximum Likelihood.

Table 2. Contrast of epidemiologic and phylodynamic data in Latin America up to the date of last sampled sequence reported for each
country.

	Observed					Inferred					
Country	Re	CI95%	Date of introduction	Cumulative infections	Days after LSS	Re	CI95%	TMRA	CI95%	Cumulative infections	CI95%
Argentina	1·29	1·22 to 1·36	2020-03-03	2,828	47	1·50	1·22 to 1·83	2020-02-08	2020-02-07 to 2020-02-09	65,510	57,407 to 104,413
Brazil	1·47	1·46 to 1·49	2020-02-25	61,888	62	1·27	1·05 to 1·53	2020-02-05	2020-02-04 to 2020-02-05	99,561	55,489 to 218,189
Chile	1·72	1·65 to 1·79	2020-03-03	4,471	34	3·14	2·57 to 3·76	2020-02-12	2020-02-12 to 2020-02-13	220,414	142,804 to 400,157
Colombia	1·61	1·50 to 1·72	2020-03-06	1,579	50	1·30	1·09 to 1·58	2020-02-13	2020-02-12 to 2020-02-14	110,778	73,377 to 203,661
Costa Rica	2·10	1·69 to 2·56	2020-03-06	177	19	2·22	1·17 to 4·06	2020-03-07	2020-03-05 to 2020-03-08	390,403	255,409 to 728,273
Mexico	3·18	2·6 to 3·84	2020-02-28	203	22	1·49	1·21 to 1·82	2020-02-04	2020-02-03 to 2020-02-05	122,945	108,829 to 236,820
Uruguay	1·10	0·97 to 1·24	2020-03-13	535	39	1·35	0·84 to 2·04	2020-03-05	2020-03-04 to 2020-03-05	120,884	74,602 to 291,320

Re: Effective reproductive number, LSS: Last Sampled Sequence, TMRA: Time to most recent ancestor. Cumulative infections and Re
correspond to those observed or inferred up to the date of LSS.

Figure 1. Epidemic curve estimated through Maximum Likelihood (A), and Time-

dependent analysis of Effective Reproductive Number, Re (B) in Latin America up to June

4th, 2020.

B.1.1.10

B.1.1

B.1.1

B.1

B.1.8

B

B.2

B.2.1

B.2.5

B.6

B.3

A

A5

A2

A1

B.1.3

B.1.1.1

B.1.1

B.1

B.1.5

B.1.5.4

B.1.5

B.1

467 **Figure 2.** Maximum likelihood phylogenetic relationships between SARS-CoV-2 full

468 genome sequences of Latin America data set. Branch lengths estimated as nucleotide

469 substitutions per site.

Figure 3. Contrast of inferred (red) and observed (blue) daily incident cases by country since the time to most recent ancestor (TMRA) to last sampled date (LSD). Lines were fitted using a gamma model. Shaded areas correspond to the IC95%. Please note that the scale varies for each country.